TCG Lifesciences & CarnaBio enter into Strategic Alliance ‘Kinase’ Based Drug Discovery Service

Oct. 12, 2010 - PRLog -- Kolkata, October 12, 2010: TCG Lifesciences, Ltd (“TCGLS”) of India and Carna Biosciences, Inc (“CarnaBio”) of Japan have entered into a strategic alliance to collaborate and provide jointly, high end drug discovery services focusing on kinase targets, to the global pharma and biotech companies.

CarnaBio and TCGLS possess complementary capabilities and, by virtue of this alliance, expect to jointly address the research and development needs of their existing and future customers by offering seamless services through the entire drug discovery and development value chain in selected therapeutic areas which target on kinases.

CarnaBio’s President & CEO Dr. Yoshino commented on the collaboration, “With our expertise in kinase based discovery services including HTS, the broadest kinase profiling panel, and related services  and TCGLS’ capabilities in integrated drug discovery and development offerings, we are sure that this alliance will enhance the reach and capabilities of both organizations and will result in high-end services and innovative solutions for the pharma and biotech industry, helping them to develop new drugs”.

Commenting on this new alliance, Swapan Bhattacharya, Managing Director of TCGLS, said “our relationship with CarnaBio began by TCGLS providing chemistry services to support CarnaBio’s internal research programs and now has blossomed into a strategic relationship that hopes to deliver higher value addition to our respective customers by combining the unique capabilities and best practices of both organizations. Kinase based targets are in high demand today particularly for the discovery of novel therapeutics for cancer. Based on the synergies derived from our complementary skills, we hope to leverage this deep domain expertise in the quest for discovery of high value drug candidates for our pharma partners.”

About TCG Lifesciences Limited
TCG Lifesciences Limited is a leading Contract Research Services, clinical research and laboratory informatics company with operations in India, Europe, Japan and the United States.  It is part of The Chatterjee Group, a global investment conglomerate headquartered in New York.  TCGLS collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its 3 units Chembiotek (Discovery Research), Clininvent (Clinical Research Solutions) & LabVantage (Enterprise Informatics). It has trust based relationships with a majority of the global pharmaceutical companies.  The relationships span from specific solutions and sourcing services to integrated projects across multiple domains to complete translational research programs in the drug discovery and development space.

About Carna Biosciences, Inc.
Carna Biosciences, Inc (http://www.carnabio.com) is a kinase focused company and one of the world’s leading provider of kinase proteins, assay development services,kinase profiling and screening services, and crystallography products and services CarnaBio also engages in drug discovery programs on its own and in collaboration. It has a pipeline of molecules in different stages of drug discovery using CarnaBio's innovative kinase drug discovery engine, QuickScout™ and in house chemistry and biology expertise. CarnaBio has developed an ensemble chemical library consists of kinase-focused and diverse-set compounds that maximizes a success rate of screening, over 300 high throughput screening (HTS)-ready kinase assays, and a strategic synthetic and medicinal chemistry team.